The estimated Net Worth of Viviane Monges is at least 318 千$ dollars as of 17 June 2024. Viviane Monges owns over 1,437 units of ADC Therapeutics SA stock worth over 313,483$ and over the last 3 years Viviane sold ADCT stock worth over 4,153$.
Sign up
Viviane Monges ADCT stock SEC Form 4 insiders trading
Viviane has made over 1 trades of the ADC Therapeutics SA stock since 2024, according to the Form 4 filled with the SEC. Most recently Viviane sold 1,437 units of ADCT stock worth 4,153$ on 17 June 2024.
The largest trade Viviane's ever made was selling 1,437 units of ADC Therapeutics SA stock on 17 June 2024 worth over 4,153$. On average, Viviane trades about 479 units every 0 days since 2021. As of 17 June 2024 Viviane still owns at least 106,627 units of ADC Therapeutics SA stock.
You can see the complete history of Viviane Monges stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Viviane Monges's mailing address?
Viviane's mailing address filed with the SEC is 430 MOUNTAIN AVENUE, SUITE 404, , NEW PROVIDENCE, NJ, 07974.
Insiders trading at ADC Therapeutics SA
Over the last few years, insiders at ADC Therapeutics SA have traded over 225,811$ worth of ADC Therapeutics SA stock and bought 800,000 units worth 2,248,000$ . The most active insiders traders include Ron Squarer、Victor Sandor、Group, Llc Green Jeremy Red.... On average, ADC Therapeutics SA executives and independent directors trade stock every 6 days with the average trade being worth of 281,514$. The most recent stock trade was executed by Group, Llc Green Jeremy Red... on 1 July 2024, trading 800,000 units of ADCT stock currently worth 2,248,000$.
What does ADC Therapeutics SA do?
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
What does ADC Therapeutics SA's logo look like?
Complete history of Viviane Monges stock trades at DBV Technologies、ADC Therapeutics SA
ADC Therapeutics SA executives and stock owners
ADC Therapeutics SA executives and other stock owners filed with the SEC include:
-
Dr. Michael Mulkerrin,
Head of Chemistry Manufacturing & Control and VP -
Dr. Patrick van Berkel,
Sr. VP of R&D -
Kimberly Pope,
Sr. VP & Chief HR Officer -
Dr. Peter Greaney Ph.D.,
Head of Corp. Devel. -
Susan Romanus,
Chief Compliance Officer -
Amanda Hamilton,
Investor Relations Officer -
Robert A. Schmidt,
VP, Corp. Controller & Chief Accounting Officer -
Jennifer Creel,
Chief Financial Officer -
Michael Forer L.L.B.,
Vice Chairman, Exec. VP & Gen. Counsel -
Dr. Christopher J. Martin Ph.D.,
Co-Founder, CEO & Director -
Ron Squarer,
Director -
Viviane Monges,
Director -
Thomas Pfisterer,
Director -
Victor Sandor,
Director -
Peter Hug,
Director -
Jean Pierre Bizzari,
Director -
Robert Azelby,
Director -
Group, Llc Green Jeremy Red...,
-
Ameet Mallik,
Chief Executive Officer